Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2024
Reporting Period: Event-based disclosure regarding upcoming clinical data presentation and third-quarter 2024 financial results.
Key Financial Metrics
This filing is a Regulation FD disclosure and does not contain specific financial statements. The document references an upcoming conference call to review third-quarter 2024 financial results but does not provide values for revenue, profit, cash flow, margins, debt, or liquidity within this text.
Material Changes
No material financial changes are reported in this document. The primary material event is the announcement of upcoming clinical trial data presentation for the Company's lead candidate, BRTX-100.
Outlook, Management Commentary, and Risks
- Clinical Trial Update: The Company will present additional preliminary 26–52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 for subjects with chronic lumbar disc disease.
- Event Details: The presentation will be delivered by Francisco Silva, Vice President of Research and Development, at the Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) 7th International Spine Research Symposium on November 13, 2024.
- Investor Communication: A webcasted conference call with a slide presentation is scheduled for November 13, 2024, at 4:30 p.m. ET to review the clinical data, third-quarter 2024 financial results, and provide a business update.
- Legal Disclaimer: The information in the associated press release is furnished, not filed, and is not incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Verify the content of the press release (Exhibit 99.1) for specific details on the BRTX-100 clinical trial data.
- Attend or review the recording of the November 13, 2024, conference call for third-quarter 2024 financial results and liquidity status.
- Monitor the Company's website for the slide presentation accompanying the clinical data release.
- Confirm the status of the Phase 2 clinical trial for BRTX-100 in chronic lumbar disc disease following the data presentation.